BrainsWay to Present at the Oppenheimer 31st Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BrainsWay Ltd. (NASDAQ: BWAY) has announced that Christopher von Jako, CEO, will present at the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. The presentation is scheduled for 10:00 AM ET on March 16, 2021. Investors can also participate in one-on-one meetings during the event. BrainsWay specializes in non-invasive neurostimulation products, having received FDA marketing authorization for treatments targeting major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
Details
News Market Reaction – BWAY
The recorded move for BWAY in the trading session of this news was -1.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRESSKILL, N.J. and JERUSALEM, March 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference taking place on March 16-18, 2021. The Company will also host one-on-one investor meetings at the conference.
Details on the presentation can be found below.
| Date: | Tuesday, March 16, 2021 |
| Time: | 10:00 AM ET |
| Webcast Link: | https://wsw.com/webcast/oppenheimer9/bway/2729199 |
About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.
Contacts:
BrainsWay:
Hadar Levy
SVP and General Manager
HadarL@brainsway.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.